Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland.
Lausanne University Hospital, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.
ESMO Open. 2022 Dec;7(6):100612. doi: 10.1016/j.esmoop.2022.100612. Epub 2022 Nov 11.
Alectinib is a preferred first-line therapy for patients with advanced anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) in several national clinical practice guidelines. The randomized, global, phase III ALEX study has demonstrated significant improvement in progression-free survival for alectinib over crizotinib in treatment-naive ALK-positive NSCLC. It was also the first study to show clinically meaningful improvement in overall survival for a next-generation ALK tyrosine kinase inhibitor relative to crizotinib. The J-ALEX and ALESIA phase III studies confirmed the clinical benefit of alectinib relative to crizotinib in the first-line ALK-positive NSCLC treatment setting in Japanese and Asian patients, respectively. Across these pivotal phase III trials, alectinib had a manageable, well-characterized safety profile. Here, we review the safety and tolerability of long-term alectinib treatment in patients with advanced ALK-positive NSCLC and provide guidance for physicians, based on clinical experience, on the management of the most frequently reported adverse events (AEs). Most AEs associated with alectinib can be managed by dose reduction. Some alectinib-related AEs are not yet fully characterized, including myalgia and peripheral oedema and deciphering their underlying mechanism of action could enhance their management. With longer-term follow-up, the safety profile of alectinib continues to remain consistent in the ALEX study, with no new safety signals observed. Safety and tolerability data from the first-line phase III alectinib trials are also consistent with those observed in clinical trials of alectinib in later-line settings. These results add to the weight of evidence recommending alectinib as a preferred therapy for treatment-naive advanced ALK-positive NSCLC.
阿来替尼是几种国家临床实践指南中晚期间变性淋巴瘤激酶(ALK)阳性非小细胞肺癌(NSCLC)患者的首选一线治疗药物。随机、全球、III 期 ALEX 研究表明,阿来替尼在未经治疗的 ALK 阳性 NSCLC 患者中的无进展生存期显著优于克唑替尼。它也是第一个证明下一代 ALK 酪氨酸激酶抑制剂相对于克唑替尼在总生存期方面具有临床意义的改善的研究。J-ALEX 和 ALESIA III 期研究分别证实了阿来替尼在日本和亚洲患者一线 ALK 阳性 NSCLC 治疗环境中相对于克唑替尼的临床获益。在这些关键的 III 期试验中,阿来替尼具有可管理、特征明确的安全性特征。在这里,我们根据临床经验,回顾了阿来替尼治疗晚期 ALK 阳性 NSCLC 患者的长期安全性和耐受性,并为医生提供了管理最常报告的不良事件(AE)的指导。大多数与阿来替尼相关的 AE 可以通过减少剂量来管理。一些阿来替尼相关的 AE 尚未完全确定,包括肌痛和外周水肿,解析其潜在的作用机制可能会增强对它们的管理。随着随访时间的延长,阿来替尼在 ALEX 研究中的安全性特征仍然一致,未观察到新的安全性信号。阿来替尼一线 III 期试验的安全性和耐受性数据也与在后期线治疗环境中阿来替尼临床试验中观察到的数据一致。这些结果增加了推荐阿来替尼作为一线治疗未经治疗的晚期 ALK 阳性 NSCLC 的首选治疗方法的证据权重。